Treating metastatic cancer with nanotechnology
10.1038/nrc3180
Crossref journal-article
Springer Science and Business Media LLC
Nature Reviews Cancer (297)
Bibliography

Schroeder, A., Heller, D. A., Winslow, M. M., Dahlman, J. E., Pratt, G. W., Langer, R., Jacks, T., & Anderson, D. G. (2011). Treating metastatic cancer with nanotechnology. Nature Reviews Cancer, 12(1), 39–50.

Authors 8
  1. Avi Schroeder (first)
  2. Daniel A. Heller (additional)
  3. Monte M. Winslow (additional)
  4. James E. Dahlman (additional)
  5. George W. Pratt (additional)
  6. Robert Langer (additional)
  7. Tyler Jacks (additional)
  8. Daniel G. Anderson (additional)
References 226 Referenced 1,003
  1. Howlader, N. et al. SEER cancer statistics review 1975–2008. National Cancer Institute [online] (2011). / National Cancer Institute by N Howlader (2011)
  2. Steeg, P. S. Tumor metastasis: mechanistic insights and clinical challenges. Nature Med. 12, 895–904 (2006). (10.1038/nm1469) / Nature Med. by PS Steeg (2006)
  3. Sharp, P. A. & Langer, R. Research agenda. Promoting convergence in biomedical science. Science 333, 527 (2011). (10.1126/science.1205008) / Science by PA Sharp (2011)
  4. Safra, T. et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann. Oncol. 11, 1029–1033 (2000). (10.1023/A:1008365716693) / Ann. Oncol. by T Safra (2000)
  5. Tomao, S,. Miele, E,. Spinelli, G. P,. Miele, E. & Tomao, F. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int. J. Nanomedicine 4, 99–105 (2009). (10.2147/IJN.S3061) / Int. J. Nanomedicine by S Tomao (2009)
  6. Harisinghani, M. G. et al. A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation. Urology 66, 1066–1071 (2005). (10.1016/j.urology.2005.05.049) / Urology by MG Harisinghani (2005)
  7. Shih, H. A. et al. Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int. J. Radiat. Oncol. Biol. Phys. 63, 1262–1269 (2005). (10.1016/j.ijrobp.2005.07.952) / Int. J. Radiat. Oncol. Biol. Phys. by HA Shih (2005)
  8. Duncan, R. & Gaspar, R. Nanomedicine(s) under the microscope. Mol. Pharm. 5 Oct 2011 (doi:10.1021/mp200394t).
  9. Wang, J,. Tian, S,. Petros, R. A,. Napier, M. E. & Desimone, J. M. The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J. Am. Chem. Soc. 132, 11306–11313 (2010). (10.1021/ja1043177) / J. Am. Chem. Soc. by J Wang (2010)
  10. Li, Z. et al. Nanoparticle delivery of anti-metastatic NM23-H1 gene improves chemotherapy in a mouse tumor model. Cancer Gene Ther. 16, 423–429 (2009). (10.1038/cgt.2008.97) / Cancer Gene Ther. by Z Li (2009)
  11. Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067–1070 (2010). This paper describes the first therapeutic siRNA knockdown in humans. (10.1038/nature08956) / Nature by ME Davis (2010)
  12. Li, S. D,. Chono, S. & Huang, L. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol. Ther. 16, 942–946 (2008). (10.1038/mt.2008.51) / Mol. Ther. by SD Li (2008)
  13. Ma, L. et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nature Cell Biol. 12, 247–256 (2010). (10.1038/ncb2024) / Nature Cell Biol. by L Ma (2010)
  14. Ma, L,. Teruya-Feldstein, J. & Weinberg, R. A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449, 682–688 (2007). (10.1038/nature06174) / Nature by L Ma (2007)
  15. Ma, L. et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nature Biotech. 28, 341–347 (2010). (10.1038/nbt.1618) / Nature Biotech. by L Ma (2010)
  16. Gupta, R. A. et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464, 1071–1076 (2010). (10.1038/nature08975) / Nature by RA Gupta (2010)
  17. Pecot, C. V,. Calin, G. A,. Coleman, R. L,. Lopez-Berestein, G. & Sood, A. K. RNA interference in the clinic: challenges and future directions. Nature Rev. Cancer 11, 59–67 (2011). (10.1038/nrc2966) / Nature Rev. Cancer by CV Pecot (2011)
  18. Zamora-Avila, D. E. et al. WT1 gene silencing by aerosol delivery of PEI-RNAi complexes inhibits B16-F10 lung metastases growth. Cancer Gene Ther. 16, 892–899 (2009). (10.1038/cgt.2009.35) / Cancer Gene Ther. by DE Zamora-Avila (2009)
  19. Park, J. H. et al. Cooperative nanoparticles for tumor detection and photothermally triggered drug delivery. Adv. Mater. 22, 880–885 (2010). (10.1002/adma.200902895) / Adv. Mater. by JH Park (2010)
  20. von Maltzahn, G. et al. SERS-coded gold nanorods as a multifunctional platform for densely multiplexed near-infrared imaging and photothermal heating. Adv. Mater. 21, 3175–3180 (2009). (10.1002/adma.200803464) / Adv. Mater. by G von Maltzahn (2009)
  21. Gabizon, A,. Shmeeda, H. & Barenholz, Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42, 419–436 (2003). (10.2165/00003088-200342050-00002) / Clin. Pharmacokinet. by A Gabizon (2003)
  22. Lee, J. et al. Nucleic acid-binding polymers as anti-inflammatory agents. Proc. Natl Acad. Sci. USA 108, 14055–14060 (2011). (10.1073/pnas.1105777108) / Proc. Natl Acad. Sci. USA by J Lee (2011)
  23. Hood, J. D. et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404–2407 (2002). (10.1126/science.1070200) / Science by JD Hood (2002)
  24. Murphy, E. A. et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc. Natl Acad. Sci. USA 105, 9343–9348 (2008). (10.1073/pnas.0803728105) / Proc. Natl Acad. Sci. USA by EA Murphy (2008)
  25. Gupta, P. B. et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645–659 (2009). (10.1016/j.cell.2009.06.034) / Cell by PB Gupta (2009)
  26. Aboody, K. S. et al. Development of a tumor-selective approach to treat metastatic cancer. PLoS ONE 1, e23 (2006). (10.1371/journal.pone.0000023) / PLoS ONE by KS Aboody (2006)
  27. Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50–56 (2001). (10.1038/35065016) / Nature by A Muller (2001)
  28. Peer, D. & Margalit, R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int. J. Cancer 108, 780–789 (2004). (10.1002/ijc.11615) / Int. J. Cancer by D Peer (2004)
  29. Poon, Z. et al. Ligand-clustered “patchy” nanoparticles for modulated cellular uptake and in vivo tumor targeting. Angew. Chem. Int. Ed. Engl. 49, 7266–7270 (2010). (10.1002/anie.201003445) / Angew. Chem. Int. Ed. Engl. by Z Poon (2010)
  30. Ali, O. A,. Emerich, D,. Dranoff, G. & Mooney, D. J. In situ regulation of DC Subsets and T cells mediates tumor regression in mice. Sci. Transl. Med. 1, 8–19 (2009). (10.1126/scitranslmed.3000359) / Sci. Transl. Med. by OA Ali (2009)
  31. Timko, B. P,. Dvir, T. & Kohane, D. S. Remotely triggerable drug delivery systems. Adv. Mater. 22, 4925–4943 (2010). (10.1002/adma.201002072) / Adv. Mater. by BP Timko (2010)
  32. Fischel-Ghodsian, F,. Brown, L,. Mathiowitz, E,. Brandenburg, D. & Langer, R. Enzymatically controlled drug delivery. Proc. Natl Acad. Sci. USA 85, 2403–2406 (1988). (10.1073/pnas.85.7.2403) / Proc. Natl Acad. Sci. USA by F Fischel-Ghodsian (1988)
  33. Schroeder, A. et al. Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility. Langmuir 23, 4019–4025 (2007). (10.1021/la0631668) / Langmuir by A Schroeder (2007)
  34. Dromi, S. et al. Pulsed-high intensity focused ultrasound and low temperature sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin. Cancer Res. 13, 2722–2727 (2007). (10.1158/1078-0432.CCR-06-2443) / Clin. Cancer Res. by S Dromi (2007)
  35. Burks, S. R. et al. Investigation of cellular and molecular responses to pulsed focused ultrasound in a mouse model. PLoS ONE 6, e24730 (2011). (10.1371/journal.pone.0024730) / PLoS ONE by SR Burks (2011)
  36. Lu, J,. Choi, E,. Tamanoi, F. & Zink, J. I. Light-activated nanoimpeller-controlled drug release in cancer cells. Small 4, 421–426 (2008). (10.1002/smll.200700903) / Small by J Lu (2008)
  37. Kuruppuarachchi, M,. Savoie, H,. Lowry, A,. Alonso, C. & Boyle, R. W. Polyacrylamide nanoparticles as a delivery system in photodynamic therapy. Mol. Pharm. 8, 920–931 (2011). (10.1021/mp200023y) / Mol. Pharm. by M Kuruppuarachchi (2011)
  38. Wu, G. et al. Remotely triggered liposome release by near-infrared light absorption via hollow gold nanoshells. J. Am. Chem. Soc. 130, 8175–8177 (2008). (10.1021/ja802656d) / J. Am. Chem. Soc. by G Wu (2008)
  39. Derfus, A. M. et al. Remotely triggered release from magnetic nanoparticles. Adv. Mater. 19, 3932–3936 (2007). (10.1002/adma.200700091) / Adv. Mater. by AM Derfus (2007)
  40. Hoare, T. et al. Magnetically triggered nanocomposite membranes: a versatile platform for triggered drug release. Nano Lett. 11, 1395–1400 (2011). (10.1021/nl200494t) / Nano Lett. by T Hoare (2011)
  41. Lal, S,. Clare, S. E. & Halas, N. J. Nanoshell-enabled photothermal cancer therapy: impending clinical impact. Acc. Chem. Res. 41, 1842–1851 (2008). The interaction between tissue-transparent near-infrared light and gold nanomaterials results in the rapid heating of the nanoparticle, which can kill nearby tumour cells. (10.1021/ar800150g) / Acc. Chem. Res. by S Lal (2008)
  42. Yang, W. et al. Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model? Radiology 257, 685–696 (2010). (10.1148/radiol.10100500) / Radiology by W Yang (2010)
  43. Baker, I,. Zeng, Q,. Li, W. D. & Sullivan, C. R. Heat deposition in iron oxide and iron nanoparticles for localized hyperthermia. J. Appl. Phys. 99, 08H106 (2006). (10.1063/1.2171960) / J. Appl. Phys. by I Baker (2006)
  44. Ivkov, R. et al. Application of high amplitude alternating magnetic fields for heat induction of nanoparticles localized in cancer. Clin. Cancer Res. 11, 7093s–7103s (2005). (10.1158/1078-0432.CCR-1004-0016) / Clin. Cancer Res. by R Ivkov (2005)
  45. Young, J. H,. Wang, M. T. & Brezovich, I. A. Frequency-depth-penetration considerations in hyperthermia by magnetically induced currents. Electron. Lett. 16, 358–359 (1980). (10.1049/el:19800255) / Electron. Lett. by JH Young (1980)
  46. Kennedy, J. E. High-intensity focused ultrasound in the treatment of solid tumours. Nature Rev. Cancer 5, 321–327 (2005). (10.1038/nrc1591) / Nature Rev. Cancer by JE Kennedy (2005)
  47. Ziegelberger, G. ICNIRP statement on far infrared radiation exposure. Health Phys. 91, 630–645 (2006). (10.1097/01.HP.0000240533.50224.65) / Health Phys. by G Ziegelberger (2006)
  48. Curley, S. A. et al. Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles. J. Exp. Ther. Oncol. 7, 313–326 (2008). / J. Exp. Ther. Oncol. by SA Curley (2008)
  49. Moghimi, S. M,. Hunter, A. C. & Murray, J. C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53, 283–318 (2001). (10.1016/S0031-6997(24)01494-7) / Pharmacol. Rev. by SM Moghimi (2001)
  50. Eichler, A. F. et al. The biology of brain metastases-translation to new therapies. Nature Rev. Clin. Oncol. 8, 344–356 (2011). (10.1038/nrclinonc.2011.58) / Nature Rev. Clin. Oncol. by AF Eichler (2011)
  51. Lesniak, M. S. & Brem, H. Targeted therapy for brain tumours. Nature Rev. Drug Discov. 3, 499–508 (2004). (10.1038/nrd1414) / Nature Rev. Drug Discov. by MS Lesniak (2004)
  52. Minagar, A. & Alexander, J. S. Blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 9, 540–549 (2003). (10.1191/1352458503ms965oa) / Mult. Scler. by A Minagar (2003)
  53. Kizelsztein, P,. Ovadia, H,. Garbuzenko, O,. Sigal, A. & Barenholz, Y. Pegylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis. J. Neuroimmunol. 213, 20–25 (2009). (10.1016/j.jneuroim.2009.05.019) / J. Neuroimmunol. by P Kizelsztein (2009)
  54. Jain, R. K. Physiological barriers to delivery of monoclonal-antibodies and other macromolecules in tumors. Cancer Res. 50, S814–S819 (1990). / Cancer Res. by RK Jain (1990)
  55. Enochs, W. S,. Harsh, G,. Hochberg, F. & Weissleder, R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J. Magn. Reson. Imaging 9, 228–232 (1999). (10.1002/(SICI)1522-2586(199902)9:2<228::AID-JMRI12>3.0.CO;2-K) / J. Magn. Reson. Imaging by WS Enochs (1999)
  56. Veiseh, O. et al. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res. 69, 6200–6207 (2009). (10.1158/0008-5472.CAN-09-1157) / Cancer Res. by O Veiseh (2009)
  57. Calvo, P. et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 18, 1157–1166 (2001). (10.1023/A:1010931127745) / Pharm. Res. by P Calvo (2001)
  58. Kreuter, J,. Alyautdin, R. N,. Kharkevich, D. A. & Ivanov, A. A. Passage of peptides through the blood-brain-barrier with colloidal polymer particles (nanoparticles). Brain Res. 674, 171–174 (1995). (10.1016/0006-8993(95)00023-J) / Brain Res. by J Kreuter (1995)
  59. Lockman, P. R,. Koziara, J. M,. Mumper, R. J. & Allen, D. D. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J. Drug Target. 12, 635–641 (2004). (10.1080/10611860400015936) / J. Drug Target. by PR Lockman (2004)
  60. Rousselle, C. et al. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol. 57, 679–686 (2000). (10.1124/mol.57.4.679) / Mol. Pharmacol. by C Rousselle (2000)
  61. Bisgaier, C. L,. Siebenkas, M. V. & Williams, K. J. Effects of apolipoproteins A-IV and A-I on the uptake of phospholipid liposomes by hepatocytes. J. Biol. Chem. 264, 862–866 (1989). (10.1016/S0021-9258(19)85022-6) / J. Biol. Chem. by CL Bisgaier (1989)
  62. Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357–1364 (2010). (10.1038/mt.2010.85) / Mol. Ther. by A Akinc (2010)
  63. Kreuter, J. et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target. 10, 317–325 (2002). (10.1080/10611860290031877) / J. Drug Target. by J Kreuter (2002)
  64. Michaelis, K. et al. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharmacol. Exp. Ther. 317, 1246–1253 (2006). (10.1124/jpet.105.097139) / J. Pharmacol. Exp. Ther. by K Michaelis (2006)
  65. Mahley, R. W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622–630 (1988). (10.1126/science.3283935) / Science by RW Mahley (1988)
  66. Yan, X. et al. The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochem. Biophys. Res. Commun. 328, 57–62 (2005). (10.1016/j.bbrc.2004.12.137) / Biochem. Biophys. Res. Commun. by X Yan (2005)
  67. Huwyler, J,. Wu, D. F. & Pardridge, W. M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl Acad. Sci. USA 93, 14164–14169 (1996). (10.1073/pnas.93.24.14164) / Proc. Natl Acad. Sci. USA by J Huwyler (1996)
  68. van Kasteren, S. I. et al. Glyconanoparticles allow pre-symptomatic in vivo imaging of brain disease. Proc. Natl Acad. Sci. USA 106, 18–23 (2009). (10.1073/pnas.0806787106) / Proc. Natl Acad. Sci. USA by SI van Kasteren (2009)
  69. Pollard, J. W. Macrophages define the invasive microenvironment in breast cancer. J. Leukoc. Biol. 84, 623–630 (2008). (10.1189/jlb.1107762) / J. Leukoc. Biol. by JW Pollard (2008)
  70. DeNardo, D. G,. Johansson, M. & Coussens, L. M. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 27, 11–18 (2008). (10.1007/s10555-007-9100-0) / Cancer Metastasis Rev. by DG DeNardo (2008)
  71. Afergan, E. et al. Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. J. Control. Release 132, 84–90 (2008). (10.1016/j.jconrel.2008.08.017) / J. Control. Release by E Afergan (2008)
  72. Wu, Y. J. et al. In vivo leukocyte labeling with intravenous ferumoxides/protamine sulfate complex and in vitro characterization for cellular magnetic resonance imaging. Am. J. Physiol. Cell Physiol. 293, C1698–C1708 (2007). (10.1152/ajpcell.00215.2007) / Am. J. Physiol. Cell Physiol. by YJ Wu (2007)
  73. Cheng, H. et al. Nanoparticulate cellular patches for cell-mediated tumoritropic delivery. ACS Nano 4, 625–631 (2010). (10.1021/nn901319y) / ACS Nano by H Cheng (2010)
  74. Stephan, M. T,. Moon, J. J,. Um, S. H,. Bershteyn, A. & Irvine, D. J. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nature Med. 16, 1035–1041 (2010). (10.1038/nm.2198) / Nature Med. by MT Stephan (2010)
  75. Moore, A,. Sergeyev, N,. Bredow, S. & Weissleder, R. A model system to quantitate tumor burden in locoregional lymph nodes during cancer spread. Invasion Metastasis 18, 192–197 (1998). (10.1159/000024512) / Invasion Metastasis by A Moore (1998)
  76. Raz, A,. Bucana, C,. Fogler, W. E,. Poste, G. & Fidler, I. J. Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages. Cancer Res. 41, 487–494 (1981). / Cancer Res. by A Raz (1981)
  77. Hsu, M. J. & Juliano, R. L. Interactions of liposomes with the reticuloendothelial system. II: nonspecific and receptor-mediated uptake of liposomes by mouse peritoneal macrophages. Biochim. Biophys. Acta 720, 411–419 (1982). (10.1016/0167-4889(82)90120-3) / Biochim. Biophys. Acta by MJ Hsu (1982)
  78. Tassa, C,. Shaw, S. Y. & Weissleder, R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc. Chem. Res. 44, 842–852 (2011). (10.1021/ar200084x) / Acc. Chem. Res. by C Tassa (2011)
  79. Nahrendorf, M. et al. Detection of macrophages in aortic aneurysms by nanoparticle positron emission tomography-computed tomography. Arterioscler. Thromb. Vasc. Biol. 31, 750–757 (2011). (10.1161/ATVBAHA.110.221499) / Arterioscler. Thromb. Vasc. Biol. by M Nahrendorf (2011)
  80. Harisinghani, M. G. et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348, 2491–2499 (2003). Iron oxide nanoparticles have evolved over time into effective tools for imaging the spread of metastatic cancer. (10.1056/NEJMoa022749) / N. Engl. J. Med. by MG Harisinghani (2003)
  81. Finkelstein, M. C,. Kuhn, S. H,. Schieren, H,. Weissmann, G. & Hoffstein, S. Liposome uptake by human-leukocytes - enhancement of entry mediated by human-serum and aggregated immunoglobulins. Biochim. Biophys. Acta 673, 286–302 (1981). (10.1016/0304-4165(81)90337-8) / Biochim. Biophys. Acta by MC Finkelstein (1981)
  82. Torchilin, V. P. & Papisov, M. I. Why do polyethylene glycol-coated liposomes circulate so long? J. Liposome Res. 4, 725–739 (1994). (10.3109/08982109409037068) / J. Liposome Res. by VP Torchilin (1994)
  83. Gref, R. et al. Biodegradable long-circulating polymeric nanospheres. Science 263, 1600–1603 (1994). The clinical benefits of using materials such as PEG to add 'stealth' properties to nanoparticles for systemic administration. (10.1126/science.8128245) / Science by R Gref (1994)
  84. Gabizon, A. A. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin. Cancer Res. 7, 223–225 (2001). / Clin. Cancer Res. by AA Gabizon (2001)
  85. Choi, H. S. et al. Rapid translocation of nanoparticles from the lung airspaces to the body. Nature Biotech. 28, 1300–1303 (2010). The biodistribution of nanomaterials is greatly affected by the route of administration. (10.1038/nbt.1696) / Nature Biotech. by HS Choi (2010)
  86. Allen, T. M,. Hansen, C. B. & Guo, L. S. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim. Biophys. Acta 1150, 9–16 (1993). (10.1016/0005-2736(93)90115-G) / Biochim. Biophys. Acta by TM Allen (1993)
  87. Reddy, S. T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotech. 25, 1159–1164 (2007). (10.1038/nbt1332) / Nature Biotech. by ST Reddy (2007)
  88. Akinc, A. et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nature Biotech. 26, 561–569 (2008). (10.1038/nbt1402) / Nature Biotech. by A Akinc (2008)
  89. Sadauskas, E. et al. Kupffer cells are central in the removal of nanoparticles from the organism. Part. Fibre Toxicol. 4, 10 (2007). (10.1186/1743-8977-4-10) / Part. Fibre Toxicol. by E Sadauskas (2007)
  90. Baenziger, J. U. & Fiete, D. Galactose and N-acetylgalactosamine-specific endocytosis of glycopeptides by isolated rat hepatocytes. Cell 22, 611–620 (1980). (10.1016/0092-8674(80)90371-2) / Cell by JU Baenziger (1980)
  91. Cervantes, A. et al. Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. J. Clin. Oncol. Abstr. 29 3025 (2011). (10.1200/jco.2011.29.15_suppl.3025) / J. Clin. Oncol. Abstr. by A Cervantes (2011)
  92. Maeda, H. & Matsumura, Y. EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy Preface. Adv. Drug Deliv. Rev. 63, 129–130 (2011). (10.1016/j.addr.2010.05.001) / Adv. Drug Deliv. Rev. by H Maeda (2011)
  93. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249–257 (2000). (10.1038/35025220) / Nature by P Carmeliet (2000)
  94. Yuan, F. et al. Vascular-permeability in a human tumor xenograft - molecular-size dependence and cutoff size. Cancer Res. 55, 3752–3756 (1995). / Cancer Res. by F Yuan (1995)
  95. Braet, F. & Wisse, E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp. Hepatol 1, 1 (2002). (10.1186/1476-5926-1-1) / Comp. Hepatol by F Braet (2002)
  96. Torchilin, V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 63, 131–135 (2011). (10.1016/j.addr.2010.03.011) / Adv. Drug Deliv. Rev. by V Torchilin (2011)
  97. Adiseshaiah, P. P,. Hall, J. B. & McNeil, S. E. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2, 99–112 (2010). (10.1002/wnan.66) / Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. by PP Adiseshaiah (2010)
  98. Edwards, D. A. et al. Large porous particles for pulmonary drug delivery. Science 276, 1868–1871 (1997). (10.1126/science.276.5320.1868) / Science by DA Edwards (1997)
  99. Azarmi, S,. Roa, W. H. & Lobenberg, R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev. 60, 863–875 (2008). (10.1016/j.addr.2007.11.006) / Adv. Drug Deliv. Rev. by S Azarmi (2008)
  100. Ilium, L. et al. Blood clearance and organ deposition of intravenously administered colloidal particles. The effects of particle size, nature and shape. Int. J. Pharm. 12, 135–146 (1982). (10.1016/0378-5173(82)90113-2) / Int. J. Pharm. by L Ilium (1982)
  101. Pinkerton, N. M. et al. Lung targeting with triggered release using gel microparticles with encapsulated nanoparticles. AICHE annual meeting Abstr. 524F (2011).
  102. Ekrami, H,. Kennedy, A. R. & Shen, W. C. Disposition of positively charged bowman-birk protease inhibitor conjugates in mice - influence of protein conjugate charge-density and size on lung targeting. J. Pharm. Sci. 84, 456–461 (1995). (10.1002/jps.2600840413) / J. Pharm. Sci. by H Ekrami (1995)
  103. Ma, Z. et al. Redirecting adenovirus to pulmonary endothelium by cationic liposomes. Gene Ther. 9, 176–182 (2002). (10.1038/sj.gt.3301636) / Gene Ther. by Z Ma (2002)
  104. Polach, K. J. et al. Delivery of siRNA to the mouse lung via a functionalized lipopolyamine. Mol. Ther. 11 Oct 2011 (doi:10.1038/mt.2011.210).
  105. Sakurai, F,. Nishioka, T,. Yamashita, F,. Takakura, Y. & Hashida, M. Effects of erythrocytes and serum proteins on lung accumulation of lipoplexes containing cholesterol or DOPE as a helper lipid in the single-pass rat lung perfusion system. Eur. J. Pharm. Biopharm. 52, 165–172 (2001). (10.1016/S0939-6411(01)00165-5) / Eur. J. Pharm. Biopharm. by F Sakurai (2001)
  106. Senior, J. H,. Trimble, K. R. & Maskiewicz, R. Interaction of positively-charged liposomes with blood: implications for their application in vivo. Biochim. Biophys. Acta 1070, 173–179 (1991). (10.1016/0005-2736(91)90160-A) / Biochim. Biophys. Acta by JH Senior (1991)
  107. Sarfati, G,. Dvir, T,. Elkabets, M,. Apte, R. N. & Cohen, S. Targeting of polymeric nanoparticles to lung metastases by surface-attachment of YIGSR peptide from laminin. Biomaterials 32, 152–161 (2010). (10.1016/j.biomaterials.2010.09.014) / Biomaterials by G Sarfati (2010)
  108. Hess, K. R. et al. Metastatic patterns in adenocarcinoma. Cancer 106, 1624–1633 (2006). (10.1002/cncr.21778) / Cancer by KR Hess (2006)
  109. Roodman, G. D. Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655–1664 (2004). (10.1056/NEJMra030831) / N. Engl. J. Med. by GD Roodman (2004)
  110. Wang, D,. Miller, S. C,. Kopeckova, P. & Kopecek, J. Bone-targeting macromolecular therapeutics. Adv. Drug Deliv. Rev. 57, 1049–1076 (2005). This paper highlights the need to develop new modalities for targeting bone metastasis. (10.1016/j.addr.2004.12.011) / Adv. Drug Deliv. Rev. by D Wang (2005)
  111. Roodman, G. D. Mechanisms of bone metastasis. Discov. Med. 4, 144–148 (2004). / Discov. Med. by GD Roodman (2004)
  112. Hengst, V,. Oussoren, C,. Kissel, T. & Storm, G. Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int. J. Pharm. 331, 224–227 (2007). (10.1016/j.ijpharm.2006.11.024) / Int. J. Pharm. by V Hengst (2007)
  113. Steeg, P. S. Metastasis suppressors alter the signal transduction of cancer cells. Nature Rev. Cancer 3, 55–63 (2003). (10.1038/nrc967) / Nature Rev. Cancer by PS Steeg (2003)
  114. Chertok, B,. David, A. E. & Yang, V. C. Brain tumor targeting of magnetic nanoparticles for potential drug delivery: effect of administration route and magnetic field topography. J. Control. Release 155, 393–399 (2011). (10.1016/j.jconrel.2011.06.033) / J. Control. Release by B Chertok (2011)
  115. Chertok, B,. David, A. E,. Huang, Y. & Yang, V. C. Glioma selectivity of magnetically targeted nanoparticles: a role of abnormal tumor hydrodynamics. J. Control. Release 122, 315–323 (2007). (10.1016/j.jconrel.2007.05.030) / J. Control. Release by B Chertok (2007)
  116. Lum, A. F. et al. Ultrasound radiation force enables targeted deposition of model drug carriers loaded on microbubbles. J. Control. Release 111, 128–134 (2006). (10.1016/j.jconrel.2005.11.006) / J. Control. Release by AF Lum (2006)
  117. von Maltzahn G. Fau - Park, J.-H. et al. Nanoparticles that communicate in vivo to amplify tumour targeting. Nature Mater. 10, 545–552 (2011). Two-part nanoparticle system, where one nanoparticle recruits a second therapeutic nanoparticle to a disease site. (10.1038/nmat3049) / Nature Mater. by G von Maltzahn (2011)
  118. Ebbens, S. J. & Howse, J. R. In pursuit of propulsion at the nanoscale. Soft Matter 6, 726–738 (2010). (10.1039/b918598d) / Soft Matter by SJ Ebbens (2010)
  119. Mallouk, T. E. & Sen, A. Powering nanorobots. Sci. Am. 300, 72–77 (2009). (10.1038/scientificamerican0509-72) / Sci. Am. by TE Mallouk (2009)
  120. Balzar, M,. Winter, M. J,. de Boer, C. J. & Litvinov, S. V. The biology of the 17–11A antigen (Ep-CAM). J. Mol. Med. 77, 699–712 (1999). (10.1007/s001099900038) / J. Mol. Med. by M Balzar (1999)
  121. Kaminski, M. S. et al. I-131-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. 352, 441–449 (2005). (10.1056/NEJMoa041511) / N. Engl. J. Med. by MS Kaminski (2005)
  122. Cheever, M. A. et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15, 5323–5337 (2009). (10.1158/1078-0432.CCR-09-0737) / Clin. Cancer Res. by MA Cheever (2009)
  123. Jain, R. K. et al. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin. Cancer Res. 16, 1289–1297 (2010). This study suggests that targeted drugs show better efficacy than untargeted ones, this may be due to higher accumulation in disease sites. (10.1158/1078-0432.CCR-09-2684) / Clin. Cancer Res. by RK Jain (2010)
  124. Torchilin, V. P,. Lukyanov, A. N,. Gao, Z. & Papahadjopoulos-Sternberg, B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc. Natl Acad. Sci. USA 100, 6039–6044 (2003). (10.1073/pnas.0931428100) / Proc. Natl Acad. Sci. USA by VP Torchilin (2003)
  125. Brannon-Peppas, L. & Blanchette, J. O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56, 1649–1659 (2004). (10.1016/j.addr.2004.02.014) / Adv. Drug Deliv. Rev. by L Brannon-Peppas (2004)
  126. Kirpotin, D. B. et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66, 6732–6740 (2006). (10.1158/0008-5472.CAN-05-4199) / Cancer Res. by DB Kirpotin (2006)
  127. Yang, W. et al. TMTP1, a novel tumor-homing peptide specifically targeting metastasis. Clin. Cancer Res. 14, 5494–5502 (2008). (10.1158/1078-0432.CCR-08-0233) / Clin. Cancer Res. by W Yang (2008)
  128. Chen, K. et al. Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. Biomaterials 30, 6912–6919 (2009). (10.1016/j.biomaterials.2009.08.045) / Biomaterials by K Chen (2009)
  129. Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nature Rev. Cancer 10, 9–22 (2010). (10.1038/nrc2748) / Nature Rev. Cancer by JS Desgrosellier (2010)
  130. Hanes, J,. Jermutus, L. & Plückthun, A. Selecting and evolving functional proteins in vitro by ribosome display. Methods Enzymol. 328, 404–430 (2000). (10.1016/S0076-6879(00)28409-7) / Methods Enzymol. by J Hanes (2000)
  131. Farokhzad, O. C. et al. Nanopartide-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 64, 7668–7672 (2004). (10.1158/0008-5472.CAN-04-2550) / Cancer Res. by OC Farokhzad (2004)
  132. Shigdar, S. et al. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci. 102, 991–998 (2011). (10.1111/j.1349-7006.2011.01897.x) / Cancer Sci. by S Shigdar (2011)
  133. Gragoudas, E. S,. Adamis, A. P,. Cunningham, E. T. Jr, Feinsod, M. & Guyer, D. R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805–2816 (2004). (10.1056/NEJMoa042760) / N. Engl. J. Med. by ES Gragoudas (2004)
  134. Hanvey, J. C. et al. Antisense and antigene properties of peptide nucleic-acids. Science 258, 1481–1485 (1992). (10.1126/science.1279811) / Science by JC Hanvey (1992)
  135. Zannetti, A. et al. Inhibition of Sp1 activity by a decoy PNA-DNA chimera prevents urokinase receptor expression and migration of breast cancer cells. Biochem. Pharmacol. 70, 1277–1287 (2005). (10.1016/j.bcp.2005.07.024) / Biochem. Pharmacol. by A Zannetti (2005)
  136. Yamada, A. et al. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice. Clin. Cancer Res. 14, 8161–8168 (2008). (10.1158/1078-0432.CCR-08-0159) / Clin. Cancer Res. by A Yamada (2008)
  137. Hartmann, L. C. et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int. J. Cancer 121, 938–942 (2007). (10.1002/ijc.22811) / Int. J. Cancer by LC Hartmann (2007)
  138. Wang, X. et al. A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano 5, 6184–6194 (2011). (10.1021/nn200739q) / ACS Nano by X Wang (2011)
  139. D'Angelica, M. et al. Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance. Mod. Pathol. 24, 1221–1228 (2011). (10.1038/modpathol.2011.82) / Mod. Pathol. by M D'Angelica (2011)
  140. Garin, J. et al. The phagosome proteome: insight into phagosome functions. J. Cell Biol. 152, 165–180 (2001). (10.1083/jcb.152.1.165) / J. Cell Biol. by J Garin (2001)
  141. Rajendran, L,. Knolker, H. J. & Simons, K. Subcellular targeting strategies for drug design and delivery. Nature Rev. Drug Discov. 9, 29–42 (2010). (10.1038/nrd2897) / Nature Rev. Drug Discov. by L Rajendran (2010)
  142. Verma, A. et al. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nature Mater. 7, 588–595 (2008). (10.1038/nmat2202) / Nature Mater. by A Verma (2008)
  143. Kabanov, A. V,. Sahay, G. & Alakhova, D. Y. Endocytosis of nanomedicines. J. Control. Release 145, 182–195 (2010). (10.1016/j.jconrel.2010.01.036) / J. Control. Release by AV Kabanov (2010)
  144. Bareford, L. A. & Swaan, P. W. Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Reviews 59, 748–758 (2007). (10.1016/j.addr.2007.06.008) / Adv. Drug Deliv. Reviews by LA Bareford (2007)
  145. Schroeder, A,. Levins, C. G,. Cortez, C,. Langer, R. & Anderson, D. G. Lipid-based nanotherapeutics for siRNA delivery. J. Internal Med. 267, 9–21 (2010). (10.1111/j.1365-2796.2009.02189.x) / J. Internal Med. by A Schroeder (2010)
  146. Goldberg, M,. Langer, R. & Jia, X. Nanostructured materials for applications in drug delivery and tissue engineering. J. Biomater Sci. Polym. Ed. 18, 241–268 (2007). (10.1163/156856207779996931) / J. Biomater Sci. Polym. Ed. by M Goldberg (2007)
  147. Torchilin, V. P. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 90, 604–610 (2008). (10.1002/bip.20989) / Biopolymers by VP Torchilin (2008)
  148. Love, K. T. et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. USA 107, 1864–1869 (2010). (10.1073/pnas.0910603106) / Proc. Natl Acad. Sci. USA by KT Love (2010)
  149. Andersen, E. S. et al. Self-assembly of a nanoscale DNA box with a controllable lid. Nature 459, 73–76 (2009). Sophisticated structures made of nucleic acids can be logically controlled to carry out delivery-related tasks. (10.1038/nature07971) / Nature by ES Andersen (2009)
  150. Zhang, W. et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin. Cancer Res. 16, 3420–3430 (2010). (10.1158/1078-0432.CCR-09-2904) / Clin. Cancer Res. by W Zhang (2010)
  151. Scarberry, K. E,. Dickerson, E. B,. Zhang, Z. J,. Benigno, B. B. & McDonald, J. F. Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles. Nanomedicine 6, 399–408 (2010). (10.1016/j.nano.2009.11.003) / Nanomedicine by KE Scarberry (2010)
  152. Galanzha, E. I. et al. In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nature Nanotechnol. 4, 855–860 (2009). (10.1038/nnano.2009.333) / Nature Nanotechnol. by E Galanzha (2009)
  153. Coffey, D. S,. Getzenberg, R. H. & DeWeese, T. L. Hyperthermic biology and cancer therapies: a hypothesis for the “Lance Armstrong effect”. JAMA 296, 445–448 (2006). (10.1001/jama.296.4.445) / JAMA by DS Coffey (2006)
  154. Ruggiero, A. et al. Paradoxical glomerular filtration of carbon nanotubes. Proc. Natl Acad. Sci. USA 107, 12369–12374 (2010). (10.1073/pnas.0913667107) / Proc. Natl Acad. Sci. USA by A Ruggiero (2010)
  155. Geng, Y. et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nature Nanotechnol. 2, 249–255 (2007). The mechanical properties and shape of the particle have great effects on the circulation time and on the ability to penetrate disease sites. (10.1038/nnano.2007.70) / Nature Nanotechnol. by Y Geng (2007)
  156. Slowing, I.I., Trewyn, B. G. & Lin, V. S. Mesoporous silica nanoparticles for intracellular delivery of membrane-impermeable proteins. J. Am. Chem. Soc. 129, 8845–8849 (2007). (10.1021/ja0719780) / J. Am. Chem. Soc. by II Slowing (2007)
  157. Gratton, S. E. et al. The effect of particle design on cellular internalization pathways. Proc. Natl Acad. Sci. USA 105, 11613–11618 (2008). (10.1073/pnas.0801763105) / Proc. Natl Acad. Sci. USA by SE Gratton (2008)
  158. Wiltschke, C. et al. A phase I study to evaluate safety, immunogenicity and antitumor activity of a HER2 multi-peptide virosome vaccine in patients with metastatic breast cancer. J. Clin. Oncol. Abstr. 26, 3055 (2008). (10.1200/jco.2008.26.15_suppl.3055) / J. Clin. Oncol. Abstr. by C Wiltschke (2008)
  159. Brunel, F. M. et al. Hydrazone ligation strategy to assemble multifunctional viral nanoparticles for cell imaging and tumor targeting. Nano Lett. 10, 1093–1097 (2010). (10.1021/nl1002526) / Nano Lett. by FM Brunel (2010)
  160. Chow, E. K. et al. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Sci. Transl. Med. 3, 73ra21 (2011). (10.1126/scitranslmed.3001713) / Sci. Transl. Med. by EK Chow (2011)
  161. Alexis, F,. Pridgen, E,. Molnar, L. K. & Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505–515 (2008). (10.1021/mp800051m) / Mol. Pharm. by F Alexis (2008)
  162. Cortez, C. et al. Influence of size, surface, cell line, and kinetic properties on the specific binding of A33 antigen-targeted multilayered particles and capsules to colorectal cancer cells. ACS Nano 1, 93–102 (2007). (10.1021/nn700060m) / ACS Nano by C Cortez (2007)
  163. Astete, C. E. & Sabliov, C. M. Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polym. Ed. 17, 247–289 (2006). (10.1163/156856206775997322) / J. Biomater. Sci. Polym. Ed. by CE Astete (2006)
  164. Murphy, E. A. et al. Targeted nanogels: a versatile platform for drug delivery to tumors. Mol. Cancer Ther. 10, 972–982 (2011). (10.1158/1535-7163.MCT-10-0729) / Mol. Cancer Ther. by EA Murphy (2011)
  165. Schroeder, A,. Kost, J. & Barenholz, Y. Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes. Chem. Phys. Lipids 162, 1–16 (2009). (10.1016/j.chemphyslip.2009.08.003) / Chem. Phys. Lipids by A Schroeder (2009)
  166. Liu, X. Q,. Song, W. J,. Sun, T. M,. Zhang, P. Z. & Wang, J. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. Mol. Pharm. 8, 250–259 (2011). (10.1021/mp100315q) / Mol. Pharm. by XQ Liu (2011)
  167. Tannock, I. F. & Rotin, D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49, 4373–4384 (1989). / Cancer Res. by IF Tannock (1989)
  168. Lee, E. S,. Gao, Z. & Bae, Y. H. Recent progress in tumor pH targeting nanotechnology. J. Control. Release 132, 164–170 (2008). (10.1016/j.jconrel.2008.05.003) / J. Control. Release by ES Lee (2008)
  169. Park, J. H. et al. Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc. Natl Acad. Sci. USA 107, 981–986 (2010). (10.1073/pnas.0909565107) / Proc. Natl Acad. Sci. USA by JH Park (2010)
  170. Libutti, S. K. et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin. Cancer Res. 16, 6139–6149 (2010). (10.1158/1078-0432.CCR-10-0978) / Clin. Cancer Res. by SK Libutti (2010)
  171. Dai, H. J,. Kam, N. W. S. & Liu, Z. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J. Am. Chem. Soc. 127, 12492–12493 (2005). (10.1021/ja053962k) / J. Am. Chem. Soc. by HJ Dai (2005)
  172. Kedmi, R,. Ben-Arie, N. & Peer, D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 26, 6867–6875 (2010). (10.1016/j.biomaterials.2010.05.027) / Biomaterials by R Kedmi (2010)
  173. Chonn, A,. Cullis, P. R. & Devine, D. V. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. 146, 4234–4241 (1991). (10.4049/jimmunol.146.12.4234) / J. Immunol. by A Chonn (1991)
  174. Reddy, J. A. et al. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res. 67, 4434–4442 (2007). (10.1158/0008-5472.CAN-07-0033) / Cancer Res. by JA Reddy (2007)
  175. Hamad, I. et al. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 4, 6629–6638 (2010). (10.1021/nn101990a) / ACS Nano by I Hamad (2010)
  176. Harashima, H,. Sakata, K,. Funato, K. & Kiwada, H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm. Res. 11, 402–406 (1994). (10.1023/A:1018965121222) / Pharm. Res. by H Harashima (1994)
  177. Chanan-Khan, A. et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann. Oncol. 14, 1430–1437 (2003). (10.1093/annonc/mdg374) / Ann. Oncol. by A Chanan-Khan (2003)
  178. Grimaldi, S,. Lisi, A,. Pozzi, D. & Santoro, N. Attempts to use liposomes and RBC ghosts as vectors in drug and antisense therapy of virus infection. Res. Virol. 148, 177–180 (1997). (10.1016/S0923-2516(97)89906-2) / Res. Virol. by S Grimaldi (1997)
  179. Pierige, F,. Serafini, S,. Rossi, L. & Magnani, M. Cell-based drug delivery. Adv. Drug Deliv. Rev. 60, 286–295 (2008). (10.1016/j.addr.2007.08.029) / Adv. Drug Deliv. Rev. by F Pierige (2008)
  180. Hu, C. M,. Zhang, L,. Aryal, S,. Cheung, C. & Fang, R. H. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA 108, 10980–10985 (2011). (10.1073/pnas.1106634108) / Proc. Natl Acad. Sci. USA by CM Hu (2011)
  181. Updike, S. J,. Wakamiya, R. T. & Lightfoot, E. N. Jr. Asparaginase entrapped in red blood cells: action and survival. Science 193, 681–683 (1976). (10.1126/science.821145) / Science by SJ Updike (1976)
  182. Kruse, C. A,. Tin, G. W. & Baldeschwieler, J. D. Stability of erythrocyte ghosts: a γ-ray perturbed angular correlation study. Proc. Natl Acad. Sci. USA 80, 1212–1216 (1983). (10.1073/pnas.80.5.1212) / Proc. Natl Acad. Sci. USA by CA Kruse (1983)
  183. Yang, F. et al. Genetic engineering of human stem cells for enhanced angiogenesis using biodegradable polymeric nanoparticles. Proc. Natl Acad. Sci. USA 107, 3317–3322 (2010). (10.1073/pnas.0905432106) / Proc. Natl Acad. Sci. USA by F Yang (2010)
  184. Rachakatla, R. S. et al. Attenuation of mouse melanoma by A/C magnetic field after delivery of bi-magnetic nanoparticles by neural progenitor cells. ACS Nano 4, 7093–7104 (2010). (10.1021/nn100870z) / ACS Nano by RS Rachakatla (2010)
  185. Bronshtein, T,. Toledano, N,. Danino, D,. Pollack, S. & Machluf, M. Cell derived liposomes expressing CCR5 as a new targeted drug-delivery system for HIV infected cells. J. Control. Release 151, 139–148 (2011). (10.1016/j.jconrel.2011.02.023) / J. Control. Release by T Bronshtein (2011)
  186. Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotech. 29, 341–345 (2011). (10.1038/nbt.1807) / Nature Biotech. by L Alvarez-Erviti (2011)
  187. Hardman, R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ. Health Perspect. 114, 165–172 (2006). (10.1289/ehp.8284) / Environ. Health Perspect. by R Hardman (2006)
  188. Lytton-Jean, A. K. R,. Langer, R. & Anderson, D. G. Five years of siRNA delivery: spotlight on gold nanoparticles. Small 7, 1932–1937 (2011). (10.1002/smll.201100761) / Small by AKR Lytton-Jean (2011)
  189. Zhang, C. et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 67, 1555–1562 (2007). (10.1158/0008-5472.CAN-06-1668) / Cancer Res. by C Zhang (2007)
  190. Bolskar, R. D. et al. First soluble M@C60 derivatives provide enhanced access to metallofullerenes and permit in vivo evaluation of Gd@C60[C(COOH)2]10 as a MRI contrast agent. J. Am. Chem. Soc. 125, 5471–5478 (2003). (10.1021/ja0340984) / J. Am. Chem. Soc. by RD Bolskar (2003)
  191. Yu, X. et al. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn. Reson. Med. 44, 867–872 (2000). (10.1002/1522-2594(200012)44:6<867::AID-MRM7>3.0.CO;2-P) / Magn. Reson. Med. by X Yu (2000)
  192. Benezra, M. et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J. Clin. Invest. 121, 2768–2780 (2011). (10.1172/JCI45600) / J. Clin. Invest. by M Benezra (2011)
  193. Jennings, L. E. & Long, N. J. 'Two is better than one'-probes for dual-modality molecular imaging. Chem. Commun. 28, 3511–3524 (2009). (10.1039/b821903f) / Chem. Commun. by LE Jennings (2009)
  194. Lee, H. Y. et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD) - conjugated radiolabeled iron oxide nanoparticles. J. Nucl. Med. 49, 1371–1379 (2008). (10.2967/jnumed.108.051243) / J. Nucl. Med. by HY Lee (2008)
  195. Lewin, M. et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nature Biotech. 18, 410–414 (2000). (10.1038/74464) / Nature Biotech. by M Lewin (2000)
  196. Rabin, O,. Perez, J. M,. Grimm, J,. Wojtkiewicz, G. & Weissleder, R. An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nature Mater. 5, 118–122 (2006). (10.1038/nmat1571) / Nature Mater. by O Rabin (2006)
  197. Hu, G. et al. Imaging of Vx-2 rabbit tumors with ανβ3-integrin-targeted 111In nanoparticles. Int. J. Cancer 120, 1951–1957 (2007). (10.1002/ijc.22581) / Int. J. Cancer by G Hu (2007)
  198. Choi, J. H. et al. Multimodal biomedical imaging with asymmetric single-walled carbon nanotube/iron oxide nanoparticle complexes. Nano Lett. 7, 861–867 (2007). (10.1021/nl062306v) / Nano Lett. by JH Choi (2007)
  199. Kim, C. S. et al. Enhanced detection of early-stage oral cancer in vivo by optical coherence tomography using multimodal delivery of gold nanoparticles. J. Biomed. Opt. 14, 034008 (2009). (10.1117/1.3130323) / J. Biomed. Opt. by CS Kim (2009)
  200. Nguyen, Q. T. et al. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc. Natl Acad. Sci. USA 107, 4317–4322 (2010). (10.1073/pnas.0910261107) / Proc. Natl Acad. Sci. USA by QT Nguyen (2010)
  201. Voura, E. B,. Jaiswal, J. K,. Mattoussi, H. & Simon, S. M. Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nature Med. 10, 993–998 (2004). (10.1038/nm1096) / Nature Med. by EB Voura (2004)
  202. Stroh, M. et al. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nature Med. 11, 678–682 (2005). (10.1038/nm1247) / Nature Med. by M Stroh (2005)
  203. Heller, D. A. et al. Multimodal optical sensing and analyte specificity using single-walled carbon nanotubes. Nature Nanotechnol. 4, 114–120 (2009). (10.1038/nnano.2008.369) / Nature Nanotechnol. by DA Heller (2009)
  204. Haes, A. J. & Van Duyne, R. P. A nanoscale optical blosensor: sensitivity and selectivity of an approach based on the localized surface plasmon resonance spectroscopy of triangular silver nanoparticles. J. Am. Chem. Soc. 124, 10596–10604 (2002). Molecules in the vicinity of gold or silver nanoparticles can be detected down to the single-molecule level, allowing sensitive analyte detection. (10.1021/ja020393x) / J. Am. Chem. Soc. by AJ Haes (2002)
  205. Zheng, G. F,. Patolsky, F,. Cui, Y,. Wang, W. U. & Lieber, C. M. Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nature Biotech. 23, 1294–1301 (2005). (10.1038/nbt1138) / Nature Biotech. by GF Zheng (2005)
  206. Bajaj, A. et al. Detection and differentiation of normal, cancerous, and metastatic cells using nanoparticle-polymer sensor arrays. Proc. Natl Acad. Sci. USA 106, 10912–10916 (2009). (10.1073/pnas.0900975106) / Proc. Natl Acad. Sci. USA by A Bajaj (2009)
  207. Cheng, H. Y. et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE 6, e17745 (2011). (10.1371/journal.pone.0017745) / PLoS ONE by HY Cheng (2011)
  208. Chinnaiyan, A. M. et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910–914 (2009). (10.1038/nature07762) / Nature by AM Chinnaiyan (2009)
  209. Heath, J. R. et al. Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood. Nature Biotech. 26, 1373–1378 (2008). (10.1038/nbt.1507) / Nature Biotech. by JR Heath (2008)
  210. Pouyssegur, J,. Dayan, F. & Mazure, N. M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441, 437–443 (2006). (10.1038/nature04871) / Nature by J Pouyssegur (2006)
  211. Denko, N. C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature Rev. Cancer 8, 705–713 (2008). (10.1038/nrc2468) / Nature Rev. Cancer by NC Denko (2008)
  212. Lopez-Otin, C. & Matrisian, L. M. Emerging roles of proteases in tumour suppression. Nature Rev. Cancer 7, 800–808 (2007). (10.1038/nrc2228) / Nature Rev. Cancer by C Lopez-Otin (2007)
  213. Cavallaro, U. & Christofori, G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nature Rev. Cancer 4, 118–132 (2004). (10.1038/nrc1276) / Nature Rev. Cancer by U Cavallaro (2004)
  214. Lin, R. Z. et al. Tumor-induced endothelial cell apoptosis: roles of NAD(P)H oxidase-derived reactive oxygen species. J. Cell. Physiol. 226, 1750–1762 (2011). (10.1002/jcp.22504) / J. Cell. Physiol. by RZ Lin (2011)
  215. Minn, A. J. et al. Genes that mediate breast cancer metastasis to lung. Nature 436, 518–524 (2005). (10.1038/nature03799) / Nature by AJ Minn (2005)
  216. Chiang, A. C. & Massague, J. Molecular basis of metastasis. N. Engl. J. Med. 359, 2814–2823 (2008). (10.1056/NEJMra0805239) / N. Engl. J. Med. by AC Chiang (2008)
  217. Nguyen, D. X. & Massague, J. Genetic determinants of cancer metastasis. Nature Rev. Genet. 8, 341–352 (2007). (10.1038/nrg2101) / Nature Rev. Genet. by DX Nguyen (2007)
  218. Brown, D. M. & Ruoslahti, E. Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell 5, 365–374 (2004). (10.1016/S1535-6108(04)00079-0) / Cancer Cell by DM Brown (2004)
  219. Miles, F. L,. Pruitt, F. L,. van Golen, K. L. & Cooper, C. R. Stepping out of the flow: capillary extravasation in cancer metastasis. Clin. Exp. Metastasis 25, 305–324 (2008). (10.1007/s10585-007-9098-2) / Clin. Exp. Metastasis by FL Miles (2008)
  220. Gay, L. J. & Felding-Habermann, B. Contribution of platelets to tumour metastasis. Nature Rev. Cancer 11, 123–134 (2011). (10.1038/nrc3004) / Nature Rev. Cancer by LJ Gay (2011)
  221. Meng, S. et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10, 8152–8162 (2004). (10.1158/1078-0432.CCR-04-1110) / Clin. Cancer Res. by S Meng (2004)
  222. Gupta, G. P. et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446, 765–770 (2007). (10.1038/nature05760) / Nature by GP Gupta (2007)
  223. Weis, S,. Cui, J,. Barnes, L. & Cheresh, D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J. Cell Biol. 167, 223–229 (2004). (10.1083/jcb.200408130) / J. Cell Biol. by S Weis (2004)
  224. Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. Nature Rev. Cancer 9, 239–252 (2009). (10.1038/nrc2618) / Nature Rev. Cancer by JA Joyce (2009)
  225. Psaila, B. & Lyden, D. The metastatic niche: adapting the foreign soil. Nature Rev. Cancer 9, 285–293 (2009). (10.1038/nrc2621) / Nature Rev. Cancer by B Psaila (2009)
  226. Christian, D. A. et al. Flexible filaments for in vivo imaging and delivery: persistent circulation of filomicelles opens the dosage window for sustained tumor shrinkage. Mol. Pharm. 6, 1343–1352 (2009). (10.1021/mp900022m) / Mol. Pharm. by DA Christian (2009)
Dates
Type When
Created 13 years, 8 months ago (Dec. 23, 2011, 12:37 a.m.)
Deposited 5 months, 1 week ago (March 16, 2025, 8:28 a.m.)
Indexed 2 weeks, 5 days ago (Aug. 7, 2025, 4:59 a.m.)
Issued 13 years, 8 months ago (Dec. 23, 2011)
Published 13 years, 8 months ago (Dec. 23, 2011)
Published Online 13 years, 8 months ago (Dec. 23, 2011)
Published Print 13 years, 7 months ago (Jan. 1, 2012)
Funders 0

None

@article{Schroeder_2011, title={Treating metastatic cancer with nanotechnology}, volume={12}, ISSN={1474-1768}, url={http://dx.doi.org/10.1038/nrc3180}, DOI={10.1038/nrc3180}, number={1}, journal={Nature Reviews Cancer}, publisher={Springer Science and Business Media LLC}, author={Schroeder, Avi and Heller, Daniel A. and Winslow, Monte M. and Dahlman, James E. and Pratt, George W. and Langer, Robert and Jacks, Tyler and Anderson, Daniel G.}, year={2011}, month=dec, pages={39–50} }